What is Bloom Science?
Founded in 2017, Bloom Science operates at the intersection of biology and data science, focusing on the development of microbiome therapeutics. The company's core mission involves identifying and engineering microbial-based drugs designed to address complex health conditions. By targeting the gut-brain axis and other systemic pathways, Bloom Science aims to provide novel treatment modalities that go beyond traditional pharmaceutical approaches. Their market position is defined by a commitment to rigorous scientific validation and the pursuit of transformative health outcomes, placing them among the emerging leaders in the techbio space.
How much funding has Bloom Science raised?
Bloom Science has raised a total of $12.1M across 2 funding rounds:
Debt
$95K
Series A
$12M
Debt (2021): $95K with participation from PPP
Series A (2021): $12M led by Joyance Partners, Bayer, Apollo Health Ventures, and ALS Investment Fund
Key Investors in Bloom Science
Joyance Partners
Joyance invests in companies that leverage science and technology to enhance quality of life across North America, Europe, and Asia, focusing on health and consumer sectors.
Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and agriculture, delivering innovative medicines and digital farming tools.
Apollo Health Ventures
Apollo Health Ventures is a transatlantic early-stage venture capital firm focused on investing in transformative healthcare companies that address age-related diseases and aging.
What's next for Bloom Science?
With the recent infusion of capital, Bloom Science is expected to prioritize the advancement of its lead candidates through preclinical and clinical milestones. The strategic focus will likely shift toward expanding internal R&D infrastructure and fostering collaborative partnerships with global life science entities. As the company matures, the emphasis will remain on demonstrating the efficacy of its microbiome platform, potentially setting the stage for future licensing agreements or further institutional financing rounds. The integration of advanced diagnostic tools and therapeutic delivery systems will be critical as the firm navigates the regulatory landscape and seeks to bring its innovative solutions to market.
See full Bloom Science company page
